Tianjin Huanhu Hospital
Tianjin, Tianjin Municipality, 300350, China
Location status: Recruiting
NCT Number: NCT07386015
This study is a prospective, multicenter, observational cohort (patient registry) designed to better understand freezing of gait (FOG), a disabling walking problem that can occur in Parkinson's disease and other related neurological conditions.The purpose of this registry is to collect long-term clinical information from patients with freezing of gait or gait and balance problems, and to explore how different causes of FOG are related to symptoms, walking patterns, falls, disease progression, and outcomes over time. The study will include participants with Parkinson's disease and other conditions associated with freezing of gait.Participants will receive standard medical care as determined by their treating physicians. No experimental drugs or study-related treatments will be assigned as part of this registry. Clinical information will be collected during routine visits and follow-up assessments, including questionnaires, walking and balance evaluations, video recordings, and other commonly used clinical tests.The information collected in this study may help improve the understanding of freezing of gait, support better risk assessment for falls, and guide future research and clinical management strategies for patients with gait and balance disorders.
Interested in participating?
Request Info30 year–85 year
All sexes
Observational
Tianjin, Tianjin Municipality, 300350, China
Location status: Recruiting
Freezing of gait (FOG) is a common and disabling gait disturbance characterized by a transient inability to initiate or maintain effective stepping. It is most frequently observed in Parkinson's disease but can also occur in other parkinsonian syndromes and neurological conditions associated with gait and balance dysfunction. Freezing of gait is associated with falls, loss of independence, reduced quality of life, and increased caregiver burden, yet its underlying mechanisms, clinical heterogeneity, and long-term trajectories remain incompletely understood.
This study is a prospective, multicenter, observational patient registry designed to systematically collect longitudinal clinical data from adults with freezing of gait, gait and balance impairment, or those at high risk for developing freezing of gait. Participants will be recruited from neurology and related specialty clinics at participating centers and followed over time as part of routine clinical care.
The registry will collect a broad range of clinical information, including but not limited to:
Demographic and clinical characteristics; Freezing of gait severity and related symptoms; Objective gait parameters and balance performance assessed using standardized gait tasks; Motor symptom severity and functional status; Falls and fall-related outcomes; Health-related quality of life and other patient-reported outcomes. Clinical assessments will be performed at baseline and during scheduled follow-up visits over a planned follow-up period of up to 36 months. Data collection may include questionnaires, clinician-rated scales, objective gait and balance assessments, and video-based evaluations, depending on local clinical practice and participant capability.
This registry is non-interventional. All diagnostic and therapeutic decisions, including medication adjustments and rehabilitative interventions, will be made solely by the treating physicians according to standard clinical practice. The study does not mandate any experimental drugs, devices, or procedures.
The primary objectives of this registry are to:
Characterize the longitudinal course and clinical variability of freezing of gait; Examine associations between freezing of gait, gait and balance impairment, falls, and clinical outcomes; Identify potential clinical phenotypes and risk factors associated with worsening gait dysfunction and adverse outcomes.
The findings from this registry are intended to support hypothesis generation, improve clinical risk assessment, and provide a foundation for the development of future mechanistic studies and interventional trials targeting freezing of gait and related gait disorders.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This is an observational patient registry. No experimental drugs, devices, or procedures are assigned as part of the study. All participants receive standard medical care, and data are collected during routine clinical visits and follow-up assessments.
Time frame: Baseline to 36 months
The New Freezing of Gait Questionnaire (NFOG-Q) is a patient-reported outcome measure assessing the severity and impact of freezing of gait in Parkinson's disease.
The total score ranges from 0 to 28, with higher scores indicating more severe freezing of gait.
The primary outcome is the change in NFOG-Q total score from baseline to 36 months.
Time frame: Baseline to 36 months
Time from baseline to the first occurrence of freezing of gait in participants without freezing of gait at baseline.
Time frame: Baseline to 36 months
Number of falls reported during follow-up, collected through clinical visits and follow-up assessments.
Time frame: Baseline to 36 months
Health-related quality of life will be assessed using the Parkinson's Disease Questionnaire-39 (PDQ-39), a validated patient-reported outcome measure for individuals with Parkinson's disease.
The PDQ-39 Summary Index score ranges from 0 to 100, with higher scores indicating worse health-related quality of life.
The outcome is defined as the change in PDQ-39 Summary Index score from baseline to 36 months.
Time frame: Baseline to 36 months
Gait speed will be measured during standardized gait tasks using an objective gait assessment system.
The outcome is defined as the change in gait speed (meters per second, m/s) from baseline to 36 months, with higher values indicating better gait performance.
Time frame: Baseline to 36 months
Stride length will be assessed during standardized gait tasks using an objective gait assessment system.
The outcome is defined as the change in stride length (meters, m) from baseline to 36 months, with higher values indicating better gait performance.
Time frame: Baseline to 36 months
Gait variability will be quantified during standardized gait tasks using an objective gait assessment system.
Gait variability will be expressed as the coefficient of variation (%) of stride length.
The outcome is defined as the change in gait variability from baseline to 36 months, with lower values indicating better gait stability.
Time frame: Baseline to 36 months
Balance performance will be assessed using the Mini-Balance Evaluation Systems Test (Mini-BESTest), a validated clinical scale for evaluating dynamic balance in patients with Parkinson's disease.
The Mini-BESTest total score ranges from 0 to 28, with higher scores indicating better balance performance.
The outcome is defined as the change in Mini-BESTest total score from baseline to 36 months.
Time frame: Baseline to 36 months.
This outcome evaluates longitudinal changes in fMRI-derived functional connectivity within and between frontal cortical regions, basal ganglia, and brainstem locomotor control areas. The objective is to construct an integrated "brain network-clinical phenotype-FOG outcome" framework, enabling identification of neural network signatures specifically associated with freezing of gait and its progression.
Contact information is provided by the study sponsor or research team.
Tianjin Huanhu Hospital
Other
FREEZE-Path Cohort: Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06713265
Basal Ganglia Diseases, Brain Diseases
Saint-Sébastien-de-Morsent, France
View Trial DetailsNCT03651856
Basal Ganglia Diseases, Brain Diseases
Charleston, South Carolina, United States
View Trial DetailsNCT02214251
Basal Ganglia Diseases, Brain Diseases
Taichung, Taiwan
View Trial DetailsNCT05292794
Basal Ganglia Diseases, Brain Diseases
Redwood City, California, United States
View Trial Details